Navigation Links
Antifungal drug delays need for chemo in advanced prostate cancer
Date:6/2/2011

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical trial led by Johns Hopkins experts, are scheduled for presentation on Saturday, June 4 at the 2011 American Society of Clinical Oncology (ASCO) annual meeting (abstract #4532).

Currently, the drug is approved to treat fungal infections in nails and other organs. Serious side effects can include heart failure, and Johns Hopkins experts caution that itraconazole needs further study before it can be considered for prostate cancer treatment.

Identified as a potential anticancer drug after Hopkins scientists scoured a database of more than 3,000 FDA-approved drugs, itraconazole appears to block tumor blood vessel growth -- the only drug in its class to do so -- much like the anticancer drug bevacizumab (Avastin). The antifungal also disrupts a key cancer-initiating biological pathway called Hedgehog. Laboratory testing by Johns Hopkins scientist Jun Liu, Ph.D., has shown that human prostate tumors implanted in mice shrink when treated with itraconazole.

"The most effective therapy we have right now for metastatic prostate cancer is hormone therapy, and when it doesn't work, the next step is usually chemotherapy," says Emmanuel Antonarakis, M.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. In a search for compounds that could put off chemotherapy, the Johns Hopkins team turned to itraconazole.

For the study, patients with prostate cancer that had spread to other organs and did not respond to hormone therapy were randomly assigned to receive low or high doses of itraconazole.

Over 24 weeks of daily treatment with oral itraconazole, the investigators tracked the length of time for each patient's prostate cancer to worsen (called progression-free survival). Evidence of worsening disease was measured by a 25 percent increase in their blood level of prostate specific antigen (PSA), a marker for prostate cancer.

Early in the trial, preliminary analysis of 17 men receiving low doses of itraconazole showed that only two of them (11.8 percent) had stable or declining PSA. Because of the limited response, no further men were given low doses of the drug.

However, 11 of 24 (48.4 percent) men taking high doses of itraconazole had stable or declining PSA levels lasting at least 24 weeks. In addition, nearly a third of men taking the high dose had PSA reductions of 30 percent or more. Metastatic prostate cancer patients receiving no treatment typically would worsen in eight to 12 weeks, according to Antonarakis.

The investigators also found that 12 of 14 men taking high doses of itraconazole had lower levels of circulating tumor cells present in their blood after therapy, compared with their baseline levels.

Seven patients experienced side effects, including low potassium, hypertension and fluid retention, but the problems were resolved with potassium replacement pills, anti-hypertension drugs, and diuretics.

"We also tested whether itraconazole acted as hormone therapy by tracking levels of testosterone and DHEA (a testosterone derivative) in the blood, and we found no reductions of either testosterone or DHEA," says Antonarakis. "This finding shows that itraconazole is not just another hormone therapy, and has a unique mechanism of action."

Antonarakis and colleagues next plan to examine blood and skin samples taken from study participants specifically to look for levels of proteins linked to tumor blood vessel formation and the Hedgehog pathway.

"With these results, we believe that high-dose itraconazole is worth studying in a larger group of men with advanced prostate cancer," adds Antonarakis.


'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. New Research Uncovers Elusive Target of Antifungal Agent
2. Flat Head Syndrome Linked to Developmental Delays
3. New study reveals long delays and variability are losing the UK research and jobs
4. In brain-injured children, early gesturing predicts language delays
5. Drug that restricts blood supply to prostate tumors delays disease progression
6. Deaths From Heart Attack Rise With Delays in Care
7. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
8. Bilingualism delays onset of Alzheimers symptoms
9. Delivery Even a Bit Early May Mean Developmental Delays
10. Heart Patients With Depression Often Find ER Delays
11. Blood Pressure Drug Delays Kidney Disease in Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... her Smiling Patriot program today with a new Indiegogo campaign . ... care to homeless veterans in the Los Angeles area, either as a participating patient ...
(Date:2/23/2017)... CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... worries, or problems. He has also continued to spiritually evolve, which is the purpose ... published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide ...
(Date:2/22/2017)... Tampa, Fla. (PRWEB) , ... February 22, 2017 ... ... the field of regenerative medicine in recent years. The technology is so cutting ... sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the ... once again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping ... episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish ...
(Date:2/22/2017)... ... February 22, 2017 , ... A cylindrical “pipeline” used for ... to reach ones, according to the results of a clinical trial announced Wednesday. ... by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist Health and Lyerly ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Corp. (NYSE: NVRO), a global medical device company that is ... today reported financial results for the three months and full ... & Highlights: Achieved revenue of $228.5 million ... reported, over the prior year U.S. revenue of ... prior year International revenue of $55.2 million ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Oesophageal Cancer ... What are the key drugs marketed for Oesophageal ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
Breaking Medicine Technology: